- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02707263
Effect of Intravenous Continuous Infusion Heparin on Rates of Venous Thromboembolism in High-Risk, Critically Ill Patients
April 25, 2017 updated by: NYU Langone Health
The primary purpose of this study is to demonstrate that a continuous infusion of intravenous (IV) heparin (UFH) for Venous thromboembolism (VTE) prophylaxis will restore prophylactic levels of heparin in high-risk critically ill medical patients as compared with guideline recommended subcutaneous heparin.
Antifactor Xa assay, a laboratory test to measure the anticoagulant activity of heparin, or the ability of heparin to thin the blood, will be used to demonstrate that Intravenous administration is more effective.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
New York, New York, United States, 10016
- New York University School of Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Admission to the medical ICU (MICU)
- High-risk for Venous Thromboembolism (VTE) ≥ 1 of the following:
- Body Mass Index (BMI) ≥ 30 kg/m2
- Personal or family history of VTE
- Receiving vasopressors
Exclusion Criteria:
- Indication for therapeutic anticoagulation
- Evidence of deep vein thrombosis (DVT) on ultrasonography at admission
- Indwelling intrathecal, epidural, or other indwelling deep catheters
- Recent (< 3 months) International Society of Thrombosis and Haemostasis (ISTH) major bleeding13
- Recent (< 3 months) major trauma
- Recent (< 3 months) neurosurgery or orthopedic surgery Pregnancy
- Contraindication to heparin or heparin products
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Intravenous continuous infusion of heparin (IV UFH)
Heparin will be administered intravenously.
|
|
Active Comparator: Subcutaneous heparin
Heparin will be subcutaneously administered.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Comparison of Coagulation (Anti-Xa levels) in patients receiving Intravenous Continuous Infusion Heparin versus subcutaneous Heparin
Time Frame: 3 Days
|
3 Days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: John Papadopoulos, MD, New York University Medical School
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2016
Primary Completion (Actual)
April 1, 2017
Study Completion (Actual)
April 1, 2017
Study Registration Dates
First Submitted
March 1, 2016
First Submitted That Met QC Criteria
March 8, 2016
First Posted (Estimate)
March 14, 2016
Study Record Updates
Last Update Posted (Actual)
April 27, 2017
Last Update Submitted That Met QC Criteria
April 25, 2017
Last Verified
April 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 15-01051
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Venous Thromboembolism
-
BayerWithdrawnTotal Hip Replacement | Total Knee Replacement | Prophylaxis, Thromboembolism, Venous
-
University Hospital, BrestRecruitingVenous Thromboembolism (VTE)France
-
University of ArizonaRecruitingPediatric Venous ThromboembolismUnited States
-
National Taiwan University HospitalUnknownDeep Venous ThromboembolismTaiwan
-
Ya-Wei XuFirst Affiliated Hospital, Sun Yat-Sen University; Nanfang Hospital of Southern...RecruitingVenous Thromboembolism (VTE)China
-
Bristol-Myers SquibbCompletedVenous Thromboembolism (VTE)United States
-
BayerCompletedTreatment of Venous ThromboembolismJapan
-
Azidus BrasilUnknownPrevention of Venous ThromboembolismBrazil
-
Fadoi Foundation, ItalyCompletedPrevention of Venous ThromboembolismItaly
-
Fadoi Foundation, ItalyUniversity Of PerugiaCompletedPrevention of Venous ThromboembolismItaly
Clinical Trials on intravenous continuous infusion of heparin (IV UFH)
-
Robert F. JamesIndiana University School of MedicineSuspendedNeurobehavioral Manifestations | Aneurysmal Subarachnoid Hemorrhage | Vasospasm, Intracranial | Intracranial Aneurysm | Heparin-induced Thrombocytopenia Type IIUnited States
-
Stealth BioTherapeutics Inc.CompletedHealthy VolunteersUnited States
-
Yong Seog OhCompletedCoagulation; IntravascularKorea, Republic of
-
TakedaTakeda Development Center Americas, Inc.Active, not recruitingHunter SyndromeUnited States, Germany, Malaysia, Philippines, Thailand, Dominican Republic, Serbia, Vietnam
-
Assistance Publique - Hôpitaux de ParisCompletedPrimary PCI - STEMIFrance
-
Alnylam PharmaceuticalsCompletedTTR-mediated AmyloidosisPortugal, Sweden, Brazil, United States, France, Spain, Germany
-
University Medicine GreifswaldNovartisUnknown
-
SANE-Society of AnesthesiologyInstituto de Cardiologia do Rio Grande do Sul; Fundação Universitária de Cardiologia...CompletedCardiac Surgery | Cardiopulmonary Bypass | AnticoagulationBrazil
-
Radboud University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentCompletedObesity | Metabolic Syndrome XNetherlands
-
Bristol-Myers SquibbCompleted